MedTrace Logo

Cangrelor to Clopidogrel or Prasugrel Transition Study

NCT01979445 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-02-26

Study results available
· View outcomes & findings →

Summary

There are two separate objectives in this study:

1. To demonstrate the pharmacodynamic (PD) profile when participants treated with cangrelor are switched to oral prasugrel 60 mg administered 30 minutes (min) after cangrelor infusion is discontinued
2. To demonstrate the PD profile when participants treated with cangrelor are switched to oral clopidogrel 600 mg administered during or immediately after cangrelor infusion.

Conditions

  • Coronary Artery Disease (CAD)

Interventions

DRUG

Cangrelor

Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.

DRUG

Clopidogrel

Clopidogrel 600 mg single oral dose

DRUG

Prasugrel

Prasugrel 60 mg single oral dose

Sponsors & Collaborators

  • The Medicines Company

    lead INDUSTRY

Principal Investigators

  • David J. Schneider, MD · University of Vermont Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-02
Primary Completion
2014-01-20
Completion
2014-01-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01979445 on ClinicalTrials.gov